ProQR Therapeutics (PRQR) Non-Current Deffered Revenue (2015 - 2026)

ProQR Therapeutics (PRQR) has reported Non-Current Deffered Revenue for 11 consecutive years, with $19.7 million the latest figure, recorded in Q1 2026.

• Quarterly Non-Current Deffered Revenue fell 38.84% year-over-year to $19.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.7 million (down 38.84% YoY) and the FY2025 annual result came in at $24.3 million, down 27.3% from the prior year.
• Non-Current Deffered Revenue eased to $19.7 million in Q1 2026 per PRQR's latest filing, from $24.3 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for PRQR reached as high as $74.6 million in Q4 2022 and fell as low as $12.8 million in Q3 2022.
• A 5-year average of $38.4 million and a median of $33.5 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• The largest YoY upside for Non-Current Deffered Revenue was 2377268.42% in 2022 against a maximum downside of 43.66% in 2022.
• Year by year, Non-Current Deffered Revenue stood at $74.6 million in 2022, then tumbled by 32.63% to $50.3 million in 2023, then plunged by 33.37% to $33.5 million in 2024, then slipped by 27.3% to $24.3 million in 2025, then declined by 19.1% to $19.7 million in 2026.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $19.7 million, $24.3 million, and $27.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.